The company has reported a net loss of $1.38m, or $0.02 loss per diluted share, compared to net loss of $1.61m or $0.02 loss per diluted share, for the same period last year.
Antares Pharma‘s operating loss was $1.41m, as compared to $1.59m for the same period prior year.
Total gross profit increased in the first quarter of 2011 to $2.1m compared to $2m in 2010, primarily due to the increase in royalties.
Antares Pharma president and CEO Paul Wotton said in addition to a solid operational performance, the first quarter brought a number of important events including the FDA acceptance and granting of a filing fee waiver for their NDA filing for Anturol for OAB.
"We are also excited by the continued development of the novel Vibex MTX product," Wotton said.